Patents by Inventor Niels Lindner
Niels Lindner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230141809Abstract: The present invention covers new quinoline compounds of general formula (I): in which A, R1, R2, R3, R4, R5, R6, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: December 9, 2022Publication date: May 11, 2023Inventors: Walter HUEBSCH, Nils GRIEBENOW, Hans-Georg SCHWARZ, Daniel KULKE, Claudia BOEHM, Kirsten BOERNGEN, Bernd ALIG, Wei ZHUANG, Iring HEISLER, Thomas ILG, Johannes KOEBBERLING, Adeline KOEHLER, Niels LINDNER, Ulrich GOERGENS, Claudia WELZ, Maike HINK
-
Publication number: 20230115270Abstract: The present application relates to novel substituted heterocyclic carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases and to their use for producing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of breathing difficulties including sleep-induced breathing difficulties such as central and obstructive sleep apnoea, snoring (primary and obstructive snoring), dysphagia, peripheral and cardiac vascular disorders including diabetic microangiopathies and disorders of the peripheral and central nervous system including neurodegenerative and neuroinflammatory disorders.Type: ApplicationFiled: November 5, 2020Publication date: April 13, 2023Applicants: Bayer Aktiengesellschaft, Bayer AktiengesellschaftInventors: Martina DELBECK, Michael HAHN, Thomas MÜLLER, Lisa DIETZ, Magdalena PLATZK, Daniel MEIBOM, Philipp BUCHGRABER, Niels LINDNER, Eva Maria BECKER-PELSTER, Carsten SCHMECK
-
Publication number: 20230065629Abstract: The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: November 4, 2021Publication date: March 2, 2023Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Anja GIESE, Jürgen KLAR, Alexander Helmut Michael EHRMANN, Jens WILLWACHER, David ENGEL, Andre Philippe DIESKAU, Antje KAHNERT, Alexey GROMOV, Carsten SCHMECK, Niels LINDNER, Thomas MÜLLER, Anna Lena ANDREEVSKI, Jan DREHER, Karl COLLINS
-
Patent number: 11572357Abstract: The present invention covers new quinoline compounds of general formula (I), in which A, R1, R2, R3, R4, R5, R6, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.Type: GrantFiled: May 7, 2019Date of Patent: February 7, 2023Assignee: Bayer Animal Health GmbHInventors: Walter Hübsch, Nils Griebenow, Hans-Georg Schwarz, Daniel Kulke, Claudia Böhm, Kirsten Börngen, Bernd Alig, Wei Zhuang, Iring Heisler, Thomas Ilg, Johannes Köbberling, Adeline Köhler, Niels Lindner, Ulrich Görgens, Claudia Welz, Maike Hink
-
Publication number: 20230027985Abstract: The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, 5- to 6-membered heteroaryl or phenyl; R2 is hydrogen or alkyl; A is 5-membered heteroaryl; Z is 6- to 10-membered aryl or 5- to 10-membered heteroaryl; all groups being optionally substituted.Type: ApplicationFiled: November 12, 2020Publication date: January 26, 2023Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc.Inventors: Daniel MEIBOM, Yolanda CANCHO GRANDE, Pierre WASNAIRE, Sarah Anna Liesa JOHANNES, Niels LINDNER, Kristin BEYER, Till FREUDENBERGER, Damian BROCKSCHNIEDER, Ilka MATHAR, Jürgen KLAR, Dmitry ZUBOV, Dzianis MENSHYKAU, Tanja KRAINZ, Eric STEFAN, Bryan MACDONALD, Yi XING, Nadine ELOWE, Guzman SANCHEZ
-
Patent number: 11505545Abstract: The present invention covers new quinoline compounds of general formula (I): in which A, R1, R2, R3, R4, R5, R6, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.Type: GrantFiled: October 30, 2020Date of Patent: November 22, 2022Assignee: Bayer Animal Health GmbHInventors: Walter Hübsch, Johannes Köbberling, Adeline Köhler, Hans-Georg Schwarz, Daniel Kulke, Claudia Welz, Thomas Ilg, Kirsten Börngen, Wei Zhuang, Nils Griebnow, Claudia Böhm, Niels Lindner, Maike Hink, Ulrich Görgens
-
Publication number: 20220324865Abstract: The invention relates to substituted dihydropyrazolo pyrazine carboxamide derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and diabetes, and also urogenital and ophthalmic disorders.Type: ApplicationFiled: May 10, 2019Publication date: October 13, 2022Inventors: Steffen MUELLER, Rudolf SCHOHE-LOOP, Nuria ORTEGA HERNANDEZ, Frank SUESSMEIER, Eloisa JIMENEZ NUNEZ, Thomas BRUMBY, Niels LINDNER, Christoph GERDES, Elisabeth POOK, Anja BUCHMUELLER, Fabienne Zdenka GAUGAZ, Dieter LANG, Stefanie ZIMMERMANN, Alexander Helmut Michael EHRMANN, Michael GERISCH, Lutz LEHMANN, Andreas TIMMERMANN, Martina SCHAEFER, Georg SCHMIDT, Karl-Heinz SCHLEMMER, Markus FOLLMANN, Elisabeth KERSTEN, Vivian WANG, Xiang GAO, Yafeng WANG
-
Publication number: 20220259228Abstract: The present application relates to novel (imidazo[1,2-a]pyridin-3-yl)methyl-substituted diazaheterobicyclic compounds, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of respiratory disorders including sleep-related respiratory disorders such as obstructive sleep apnoea and central sleep apnoea and snoring. The present application further relates to a method of discovering a compound having TASK-1- and/or TASK-3-blocking properties.Type: ApplicationFiled: September 15, 2021Publication date: August 18, 2022Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Martina DELBECK, Michael Hahn, Thomas Müller, Klemens Lustig, Johanna Anlahr, Udo Albus, Doris Gehring, Björn Rosenstein, Karl Collins, Niels Lindner, Janine Nicolai, Moritz Beck-Broichsitter
-
Publication number: 20220017540Abstract: The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.Type: ApplicationFiled: July 16, 2021Publication date: January 20, 2022Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Martina DELBECK, Michael HAHN, Thomas MÜLLER, Klemens LUSTIG, Karl COLLINS, Niels LINDNER, Janine NICOLAI, Moritz BECK-BROICHSITTER, Udo ALBUS, Doris GEHRING, Björn ROSENSTEIN
-
Patent number: 11208400Abstract: The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.Type: GrantFiled: October 9, 2017Date of Patent: December 28, 2021Assignees: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Anja Giese, Jürgen Klar, Alexander Helmut Michael Ehrmann, Jens Willwacher, David Engel, Andre Philippe Dieskau, Antje Kahnert, Alexey Gromov, Carsten Schmeck, Niels Lindner, Thomas Müller, Anna Lena Andreevski, Jan Dreher, Karl Collins
-
Patent number: 11173151Abstract: The present invention relates to novel substituted 1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.Type: GrantFiled: October 17, 2018Date of Patent: November 16, 2021Assignees: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Marie-Pierre Collin-Kroepelin, Peter Kolkhof, Thomas Neubauer, Chantal Fuerstner, Elisabeth Pook, Matthias Beat Wittwer, Klemens Lustig, Hanna Tinel, Niels Lindner, Heiko Schirmer
-
Patent number: 11098063Abstract: The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.Type: GrantFiled: June 7, 2018Date of Patent: August 24, 2021Assignees: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Martina Delbeck, Michael Hahn, Thomas Müller, Klemens Lustig, Karl Collins, Niels Lindner, Janine Nicolai, Moritz Beck-Broichsitter, Udo Albus, Doris Gehring, Björn Rosenstein
-
Publication number: 20210139468Abstract: The present invention covers new quinoline compounds of general formula (I), in which A, R1, R2, R3, R4, R5, R6, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: May 7, 2019Publication date: May 13, 2021Inventors: Walter HÜBSCH, Nils GRIEBENOW, Hans-Georg SCHWARZ, Daniel KULKE, Claudia BÖHM, Kirsten BÖRNGEN, Bernd ALIG, Wei ZHUANG, Iring HEISLER, Thomas ILG, Johannes KÖBBERLING, Adeline KÖHLER, Niels LINDNER, Ulrich GÖRGENS, Claudia WELZ, Maike HINK
-
Publication number: 20210115026Abstract: The present invention covers new quinoline compounds of general formula (I): in which A, R1, R2, R3, R4, R5, R6, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: October 30, 2020Publication date: April 22, 2021Inventors: Walter HÜBSCH, Johannes KÖBBERLING, Adeline KÖHLER, Hans-Georg SCHWARZ, Daniel KULKE, Claudia WELZ, Thomas ILG, Kirsten BÖRNGEN, Wei ZHUANG, Nils GRIEBNOW, Claudia BÖHM, Niels LINDNER, Maike HINK, Ulrich GÖRGENS
-
Publication number: 20210024545Abstract: The present application relates to novel (imidazo[1,2-a]pyridin-3-yl)methyl-substituted diazaheterobicyclic compounds, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of respiratory disorders including sleep-related respiratory disorders such as obstructive sleep apnoea and central sleep apnoea and snoring. The present application further relates to a method of discovering a compound having TASK-1-and/or TASK-3-blocking properties.Type: ApplicationFiled: July 10, 2017Publication date: January 28, 2021Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Martina DELBECK, Michael HAHN, Thomas MÜLLER, Klemens LUSTIG, Johanna ANLAHR, Udo ALBUS, Doris GEHRING, Björn ROSENSTEIN, Karl COLLINS, Niels LINDNER, Janine NICOLAI, Moritz BECK-BROICHSITTER
-
Patent number: 10889573Abstract: The present invention covers new quinoline compounds of general formula (I) in which A, R1, R2, R3, R4, R5, R6, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment, control and/or prevention of diseases, in particular of helminth infections, as a sole agent or in combination with other active ingredients.Type: GrantFiled: November 6, 2017Date of Patent: January 12, 2021Assignee: Bayer Animal Health GMBHInventors: Walter Hübsch, Johannes Köbberling, Adeline Köhler, Hans-Georg Schwarz, Daniel Kulke, Claudia Welz, Thomas Ilg, Kirsten Börngen, Wei Zhuang, Nils Griebenow, Claudia Böhm, Niels Lindner, Maike Hink, Ulrich Görgens
-
Publication number: 20200316045Abstract: The present invention relates to novel substituted 1,2,4-triazole derivatives, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of renal and cardiovascular diseases.Type: ApplicationFiled: October 17, 2018Publication date: October 8, 2020Inventors: Marie-Pierre COLLIN-KROEPELIN, Peter KOLKHOF, Thomas NEUBAUER, Chantal FUERSTNER, Elisabeth POOK, Matthias Beat WITTWER, Klemens LUSTIG, Hanna TINEL, Niels LINDNER, Heiko SCHIRMER
-
Patent number: 10722501Abstract: The present application relates to novel substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones of formula (I), to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of lung inflammation disorders.Type: GrantFiled: May 8, 2017Date of Patent: July 28, 2020Assignees: BAYER AKTIENGESELLSCHAFT, BAYER PHARMA AKTIENGESELLSCHAFTInventors: Nicole Biber, Damian Brockschnieder, Kersten Matthias Gericke, Florian Kölling, Klemens Lustig, Jörg Meding, Heinrich Meier, Thomas Neubauer, Martina Schäfer, Andreas Timmermann, Dmitry Zubov, Carsten Terjung, Niels Lindner, Volker Badock, Dieter Moosmayer, Hideki Miyatake Ondozabal, Stephen Moore, Alexander Schulz
-
Patent number: 10662185Abstract: The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides of the general formula (I) to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.Type: GrantFiled: July 2, 2018Date of Patent: May 26, 2020Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Alexandros Vakalopoulos, Markus Follman, Ingo Hartung, Philipp Buchgraber, Rolf Jautelat, Jorma Haßfeld, Niels Lindner, Alexey Gromov, Frank Wunder, Johannes-Peter Stasch, Gorden Redlich, Volkhart Min-Jian Li, Eva Maria Becker-Pelster, Andreas Knorr
-
Publication number: 20200109155Abstract: The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.Type: ApplicationFiled: June 7, 2018Publication date: April 9, 2020Applicants: Bayer Aktiengesellschaft, Bayer Pharma AktiengesellschaftInventors: Martina DELBECK, Michael HAHN, Thomas MÜLLER, Klemens LUSTIG, Karl COLLINS, Niels LINDNER, Janine NICOLAI, Moritz BECK-BROICHSITTER, Udo ALBUS, Doris GEHRING, Björn ROSENSTEIN